Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/IIb Trial of NC-6004 Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum Failure
2018-003959-37Phase 2Terminated
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Jan 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of demplatin pegraglumer in head and neck squamous cell carcinoma (HNSCC), sponsored by NanoCarrier Co., Ltd. Primary endpoint: RPIIb dose determination. Started Jan 2019; status: terminated.
02
Drugs
demplatin pegraglumer
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-003959-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003959-37.